Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide

Clinical Cancer Research

Volumn 17, Issue 16, 2011, Pages 5473-5480

  Grossman, Stuart A ^a   Ye, Xiaobu ^a   Lesser, Glenn ^b   Sloan, Andrew ^c   Carraway, Hetty ^a   Desideri, Serena ^a   Piantadosi, Steven ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b WAKE FOREST UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CARMUSTINE; CILENGITIDE; GLIADEL WAFER; GLUCOCORTICOID; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TALAMPANEL; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CD4 LYMPHOCYTE COUNT; EDEMA; FEMALE; FOLLOW UP; GLIOMA; HUMAN; IMMUNE DEFICIENCY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERITUMORAL EDEMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CD4 LYMPHOCYTE COUNT; CHEMORADIOTHERAPY; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSION; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; TIME FACTORS;

EID: 80051693219     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0774     Document Type: Article

References (36)

1. Masur H. Prevention and treatment of pneumocystis pneumonia. N Engl J Med 1992;327:1853-1860
2. Masur H, Lane HC, Kovacs JA, Allegra CJ, Edman JC. NIH conference. Pneumocystis pneumonia: from bench to clinic. Ann Intern Med 1989;111:813-826 (Pubitemid 19283918)
3. Arend SM, Kroon FP, van't Wout JW. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases. Arch Intern Med 1995;155:2436-2441
4. Browne MJ, Hubbard SM, Longo DL, Fisher R, Wesley R, Ihde DC, et al. Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy. Ann Intern Med 1986;104:338-344 (Pubitemid 16163610)
5. Gluck T, Geerdes-Fenge HF, Straub RH, Raffenberg M, Lang B, Lode H, et al. Pneumocystis carinii pneumonia as a complication of immunosuppressive therapy. Infection 2000;28:227-230 (Pubitemid 30601421)
6. Jacobs JL, Libby DM, Winters RA, Gelmont DM, Fried ED, Hartman BJ, et al. A cluster of Pneumocystis carinii pneumonia in adults without predisposing illnesses. N Engl J Med 1991;324:246-250
7. Mansharamani NG, Balachandran D, Vernovsky I, Garland R, Koziel H. Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 2000;118:712-720
8. Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 2000;118:704-711
9. Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992;267:832-837
10. Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. more patients, same risk. Arch Intern Med 1995;155:1125-1128
11. Mahindra AK, Grossman SA. Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. J Neurooncol 2003;63:263-270 (Pubitemid 36874010)
12. Hughes MA, Parisi M, Grossman S, Kleinberg L. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys 2005;62:1423-1426 (Pubitemid 40982064)
13. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996 (Pubitemid 40349501)
14. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-1382 (Pubitemid 34177445)
15. Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004;22:610-616 (Pubitemid 41095063)
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
17. Cox DR. Regression models and life-tables. J R Stat Soc Ser B 1972;34:187-220.
18. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006;55:420-426 (Pubitemid 43887028)
19. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 2007;66:308-312 (Pubitemid 46579629)
20. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-630
21. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008;20:131-137 (Pubitemid 351339883)
22. Kleinberg L, Grossman SA, Piantadosi S, Zeltzman M, Wharam M. The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed highgrade astrocytoma. Int J Radiat Oncol Biol Phys 1999;44:535-543 (Pubitemid 29258427)
23. Lissoni P, Brivio F, Fumagalli L, Messina G, Ghezzi V, Frontini L, et al. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers 2004;19:135-140 (Pubitemid 39106939)
24. Siddiqui M, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 2006;134:596-601. (Pubitemid 44253601)
25. Ege H, Gertz MA, Markovic SN, Lacy MQ, Dispenzieri A, Hayman SR, et al. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. Br J Haematol 2008;141:792-798 (Pubitemid 351724861)
26. De Angulo G, Yuen C, Palla SL, Anderson PM, Zweidler-McKay PA. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Cancer 2008;112:407-415
27. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213 (Pubitemid 36077915)
28. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-2666 (Pubitemid 41817714)
29. Camus M, Tosolini M, Mlecnik B, Pages F, Kirilovsky A, Berger A, et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 2009;69:2685-2693
30. Behl D, Porrata LF, Markovic SN, Letendre L, Pruthi RK, Hook CC, et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006;20:29-34.
31. Porrata LF, Ristow K, Witzig TE, Tuinistra N, Habermann TM, Inwards DJ, et al. Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas. Leukemia 2007;21:2554-2556 (Pubitemid 350148906)
32. Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001;98:579-585
33. Gordan LN, Sugrue MW, Lynch JW, Williams KD, Khan SA, Moreb JS. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 2003;31:1009-1013 (Pubitemid 36722413)
34. Porrata LF, Litzow MR, Tefferi A, Letendre L, Kumar S, Geyer SM, et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 2002;16:1311-1318
35. Joao C, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, et al. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. Bone Marrow Transplant 2006;37:865-871
36. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 2011;13:324-333